Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
CAMBRIDGE, Mass., Feb. 17, 2016 -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that the Company will host a conference call and live audio webcast at 5:00 p.m. EST on Thursday, February 25, 2016, to provide a business update and to discuss its fourth quarter 2015 financial and operating results.
To listen to the live webcast of the call, please visit the "Investors" section of the Company's website at www.aegerion.com. Individuals may also participate in the call via telephone by dialing (866) 516-3002 or (760) 298-5082. Interested parties unable to join the live call may access an archived version of the webcast on Aegerion's website for up to 30 days following the call.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy, Associate Director, IR & PR 857-242-5024
